CANNABIDIVARINIC ACID (CBDVA)

If you’ve read about CBDV — cannabidivarin — you may know that it’s one of the most clinically promising minor cannabinoids, with Phase 2 trials in epilepsy and autism spectrum disorder. What you may not know is that CBDV’s acidic precursor, CBDVA (cannabidivarinic acid), has been developing its own distinct scientific identity — and the research is surprisingly compelling.

Like the relationship between CBD and CBDA, CBDVA is the raw, unheated form of CBDV found in living cannabis plants. But unlike some cannabinoid acids that exist primarily as stepping stones to their neutral forms, CBDVA has demonstrated its own pharmacological activity — including T-type calcium channel inhibition with IC₅₀ values in the low micromolar range and GPR55 antagonism — mechanisms directly relevant to seizure control (Anderson et al., 2022). Whether those mechanisms translate to viable therapeutics depends largely on solving a significant pharmacokinetic challenge.

What Is CBDVA?

Cannabidivarinic acid (CBDVA) is a naturally occurring acidic phytocannabinoid in Cannabis sativa L. It is the carboxylic acid precursor of cannabidivarin (CBDV) — the compound from which CBDV is formed when exposed to heat or light through decarboxylation. The carboxyl group (–COOH) is attached at the C-3′ position of CBDVA’s resorcinol ring, lost as CO₂ during decarboxylation to yield CBDV (MedChemExpress, n.d.; Secret Nature, 2026).

CBDVA occupies the same structural position in the CBDV series that CBDA occupies in the CBD series. It is non-psychoactive and found in trace amounts in cannabis and hemp — particularly in CBDV-rich strains and certain landrace varieties (MÜV Florida, 2025).

CBDVA vs. CBDV: Key Differences

The relationship between CBDVA and CBDV parallels that of CBDA and CBD. CBDVA is the naturally occurring acidic form in the plant; CBDV is the decarboxylated neutral form. The key question — answered for CBDVA more definitively than for some other cannabinoid acids — is whether CBDVA converts to CBDV in the body, or whether it retains its own distinct pharmacological identity.

Research has directly addressed this: following intraperitoneal injection of CBDVA in mice, CBDV was not detected in the brain or plasma — indicating that CBDVA does not undergo significant in vivo decarboxylation to CBDV after administration. This is a pharmacologically significant finding: it means CBDVA acts as itself, not as a prodrug to CBDV (New Phase Blends, 2023).

Where CBDVA Fits in the Cannabinoid Family

CBDVA is one of six recognized natural CBD-type derivatives in cannabis. It belongs to the acidic cannabinoid subclass alongside CBDA (cannabidiolic acid) and CBGA (cannabigerolic acid), all of which are now attracting research attention as potentially active compounds in their own right rather than merely inactive precursors to their neutral forms (Li et al., 2026).

The biosynthetic relationship is straightforward: cannabigerolic acid (CBGA) → cannabigerovarinic acid (CBGVA) → CBDVA via specific oxidocyclase enzymes in the plant, in the same way CBGA → CBDA via CBDAS. CBDVA then decarboxylates to CBDV upon heating. The “varin” or “VA” suffix across this series refers to the propyl (C3) side chain — one of the key structural features differentiating these compounds from their C5 counterparts (Secret Nature, 2026).

How CBDVA Works: A Multi-Target Mechanism

T-Type Calcium Channel Inhibition

The most rigorously characterized mechanism of CBDVA is its inhibition of T-type voltage-gated calcium channels — specifically Cav3.1 and Cav3.2. In a 2022 study published in Frontiers in Pharmacology, CBDVA was found to inhibit Cav3.1 channels with an IC₅₀ of 2 μM and Cav3.2 channels with an IC₅₀ of 11 μM (Anderson et al., 2022). Among all phytocannabinoids screened in that study, CBDVA (alongside CBGVA) showed the greatest magnitude of T-type channel inhibition — ≥80% inhibition at 10 μM on Cav3.1 and Cav3.2.

T-type calcium channels are critical regulators of neuronal excitability. Their overactivation is implicated in multiple forms of epilepsy — including absence seizures — and they are a validated drug target for anticonvulsant therapy (ethosuximide, for example, works through this mechanism). CBDVA’s potent T-type channel inhibition places it in mechanistically important anticonvulsant territory (Anderson et al., 2022).

GPR55 Antagonism

CBDVA also antagonizes GPR55, a G-protein-coupled receptor implicated in neurological inflammation and neuronal hyperexcitability. GPR55 antagonism has been proposed as an effective strategy for preventing seizures, and it is the same mechanism through which CBD itself is thought to contribute to its anticonvulsant effects. CBDVA’s GPR55 antagonist activity was confirmed in the same 2022 study using AlphaScreen technology (Anderson et al., 2022; Bluntys, 2025).

TRP Channel Modulation

Like other cannabinoid acids and their neutral counterparts, CBDVA is thought to modulate transient receptor potential vanilloid (TRPV) channels — particularly TRPV1, which manages calcium flow in neurons and affects both excitability and neurotransmitter release. TRPV1 is particularly relevant in epilepsy, and its modulation is one of the proposed mechanisms for CBDVA’s anticonvulsant activity (Bluntys, 2025; De Petrocellis et al., 2011, as cited in Bluntys, 2025).

Anti-Inflammatory Properties

CBDVA is classified by MedChemExpress and Sigma-Aldrich as a non-psychoactive cannabinoid with anti-inflammatory properties. The specific mechanisms are not fully characterized, but are likely related to its shared structural features with CBDA (a known COX-2 inhibitor) and its receptor interactions (MedChemExpress, n.d.; MÜV Florida, 2025).

Potential Epigenetic Modulation

Exploratory findings presented at the 2019 International Cannabinoid Research Society (ICRS) Conference suggested that CBDVA may influence gene methylation in neural tissue — a form of epigenetic regulation that, if confirmed, could be relevant to long-term seizure control. This remains the least validated of CBDVA’s proposed mechanisms and should be treated as highly preliminary (Bluntys, 2025).

What the Research Says

Anticonvulsant Activity in Hyperthermia-Induced Seizures

CBDVA was identified as an anticonvulsant against hyperthermia-induced seizures in rodent models — a particularly relevant finding given that febrile (fever-triggered) seizures are a hallmark of Dravet syndrome, a severe childhood epilepsy. These findings positioned CBDVA alongside CBDV and other propyl-chain cannabinoids as anticonvulsant candidates relevant to the Dravet phenotype (New Phase Blends, 2023; Anderson et al., 2022).

Initial Cannabinoid Screen: CBDVA as a Top Hit

In a landmark screen of multiple phytocannabinoids for anticonvulsant activity conducted by Anderson and colleagues, CBDVA was identified as one of three compounds with novel anticonvulsant properties — alongside CBGA and CBGVA. Subsequent mechanistic investigation led to the 2022 T-type channel study, where CBDVA emerged as one of the two most potent T-type channel inhibitors among all cannabinoids tested (Anderson et al., 2022).

Distinct Activity from CBDV

Importantly, CBDVA does not appear to function simply as a prodrug to CBDV. The finding that CBDVA administered to mice did not convert to detectable CBDV in plasma or brain tissue confirms that its anticonvulsant activity, T-type channel inhibition, and GPR55 antagonism are properties of CBDVA itself — not downstream effects of conversion to CBDV. This establishes CBDVA as a pharmacologically independent entity within the propyl cannabinoid family (New Phase Blends, 2023; Anderson et al., 2022).

Key Challenge: Limited Brain Penetration

The most significant pharmacological obstacle for CBDVA as a CNS therapeutic is its limited brain penetration. Research has established that the brain-plasma ratio of CBDVA is approximately 2% — meaning only about 2% of the CBDVA in the bloodstream crosses the blood-brain barrier and reaches the brain. At anticonvulsant doses in mice, this corresponds to an estimated brain concentration of approximately 5 μM — potentially within range of its T-type channel IC₅₀ values, but only at high doses that may not be clinically practical (Anderson et al., 2022).

The authors of the 2022 study explicitly noted that this limitation “would need to be surmounted” for CBDVA to advance as a therapeutic for CNS disorders. Strategies for improving brain penetration — including nanoparticle encapsulation, prodrug approaches, or structural modification — represent an active area of pharmaceutical research for cannabinoid acids more broadly.

Availability and Research Status

CBDVA is not available as a consumer supplement. It occurs in cannabis only in trace amounts and is available commercially as a certified reference material for analytical and research use (CAS 31932-13-5), supplied by companies including Sigma-Aldrich (Cerilliant) and MedChemExpress.

An interesting secondary note: CBDVA currently plays an important role in CBDV synthesis research. It is not possible to directly synthesize CBDV in its decarboxylated form — CBDVA must be produced first and then decarboxylated. This makes CBDVA an essential research material for the more clinically advanced CBDV program (Secret Nature, 2026).

Frequently Asked Questions

The Bottom Line

CBDVA started as a footnote — CBDV’s acidic precursor, present in plants but largely ignored in favor of its decarboxylated neutral form. The research of the past few years has reframed it as something more: a pharmacologically distinct anticonvulsant candidate with among the most potent T-type calcium channel inhibition measured in any phytocannabinoid, meaningful GPR55 antagonism, and confirmed activity as its own compound (not a CBDV prodrug).

The story isn’t without complications. Low brain penetration remains a real barrier to CNS therapeutic development. Human data is completely absent. And the research base, while growing, is still small. But the mechanistic profile — T-type channels, GPR55, TRP channels, potential epigenetic effects — is a genuinely multi-modal anticonvulsant toolkit that warrants serious investigation. Of all the acidic cannabinoids currently being studied, CBDVA may be the one whose story has the most significant chapters still to be written.

Nothing in this article constitutes medical advice. Always consult a qualified healthcare provider before making any decisions about supplementation or treatment.

Back to List of Cannabinoids